HomeThemesTypesDBAbout
Showing: ◈ article×◈ coronavirus×
James Grace addresses Boris Johnson’s falsehoods about the impact of the EU on the speed of our jabs.
The consequences of leaving have long been clouded, including by the impact of Covid. Now the data is firming up—and it’s not good news.
For new medical devices entering the UK market, they will only need to comply with the old, and for some, less stringent, device standard (MDR, 2002). / ... Coupled with the additional authorisation process required to reach the UK market, this may lead to delays or deter companies from selling their products in the UK altogether.
A road trip through the ancient past and shaky future of the (dis)United Kingdom. / The grim reality for Britain as it faces up to 2022 is that no other major power on Earth stands quite as close to its own dissolution.
“For restaurants, COVID-19 has temporarily overshadowed many of the anticipated effects of Brexit.”
Lewis Silkin LLP partner Brinsley Dresden explains why brands should be careful of using nationalism to try to sell products.
Prime Minister Boris Johnson says he doesn’t want border ‘restrictions’ for medicines, but that’s what his government is doing.
Labour leader Jeremy Corbyn has asked for SSP "to be increased to European levels" but exactly how much worse off are we than our continental neighbours?
The government is yet to show that its decision not to extend the Brexit transition period was the right one, argues Joe Marshall.
There is an obvious flaw in advocating Brexit on the basis that it’s less costly than the worst pandemic the world has faced in a hundred years. But this aside, the claim Covid-19 is a bigger economic shock than Brexit deserves further interrogation.
Many firms are clinging on during the coronavirus crisis and have no capacity to to contemplate failure in talks with EU.
Despite the best efforts of a cross-party coalition of MPs to stop the ‘shutdown’, Wednesday marked the end of the successful Virtual Parliament proceedings in the Commons.
With the NHS under such exceptional pressure during the coronavirus crisis, it’s easy to overlook the fact that the UK’s Brexit transition period ends on December 31. Mark Dayan takes a closer look at how these two challenges for the health service might collide, and says there is a case to err on the side of caution.